- Home
- CLLS vs IKT Comparison
CLLS vs IKT Comparison
Compare CLLS & IKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLLS
- IKT
- Stock Information
- Founded
- CLLS 1999
- IKT 2008
- Country
- CLLS France
- IKT United States
- Employees
- CLLS N/A
- IKT N/A
- Industry
- CLLS Biotechnology: Pharmaceutical Preparations
- IKT Biotechnology: Pharmaceutical Preparations
- Sector
- CLLS Health Care
- IKT Health Care
- Exchange
- CLLS Nasdaq
- IKT Nasdaq
- Market Cap
- CLLS 144.4M
- IKT 168.0M
- IPO Year
- CLLS 2007
- IKT 2020
- Fundamental
- Price
- CLLS $1.58
- IKT $2.00
- Analyst Decision
- CLLS Buy
- IKT Buy
- Analyst Count
- CLLS 3
- IKT 2
- Target Price
- CLLS $7.00
- IKT $8.00
- AVG Volume (30 Days)
- CLLS 79.4K
- IKT 113.6K
- Earning Date
- CLLS 05-27-2025
- IKT 05-14-2025
- Dividend Yield
- CLLS N/A
- IKT N/A
- EPS Growth
- CLLS N/A
- IKT N/A
- EPS
- CLLS N/A
- IKT N/A
- Revenue
- CLLS $49,217,000.00
- IKT N/A
- Revenue This Year
- CLLS $48.52
- IKT N/A
- Revenue Next Year
- CLLS $5.17
- IKT N/A
- P/E Ratio
- CLLS N/A
- IKT N/A
- Revenue Growth
- CLLS 435.38
- IKT N/A
- 52 Week Low
- CLLS $1.10
- IKT $1.12
- 52 Week High
- CLLS $3.32
- IKT $4.20
- Technical
- Relative Strength Index (RSI)
- CLLS 60.44
- IKT 46.57
- Support Level
- CLLS $1.46
- IKT $1.78
- Resistance Level
- CLLS $1.65
- IKT $2.13
- Average True Range (ATR)
- CLLS 0.08
- IKT 0.16
- MACD
- CLLS -0.00
- IKT -0.01
- Stochastic Oscillator
- CLLS 75.00
- IKT 37.61
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.